Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-1403 · 1 trial · 1 indication
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience one or more AEs will be reported.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.
| Arm | Type | Description |
|---|---|---|
| Panel A MK-1403 + additive coformulation dose 1 | EXPERIMENTAL | Participants will receive MK-1403 + additive coformulation dose 1 orally once daily. |
| Panel A Placebo + additive coformulation dose 1 | PLACEBO_COMPARATOR | Participants will receive Placebo + additive coformulation dose 1 orally once daily. |
| Panel B MK-1403 + additive coformulation dose 2 | EXPERIMENTAL | Participants will receive MK-1403 + additive coformulation dose 2 orally once daily |
| Panel B Placebo + additive coformulation dose 2 | PLACEBO_COMPARATOR | Participants will receive Placebo + additive coformulation dose 2 orally once daily |
| Name | Type | Description |
|---|---|---|
| MK-1403 + additive coformulation | DRUG | MK-1403 + additive coformulation is a co-formulated product of MK-1403 administered orally. |
| Placebo + additive coformulation | DRUG | Placebo + additive coformulation is a co-formulated product of placebo administered orally. |
Inclusion Criteria: * Has a confirmed diagnosis of Type 2 diabetes mellitus (T2DM) * Has body mass index (BMI) between 18 and 40 kg/m\^2, inclusive Exclusion Criteria: * Has Type 1 diabetes mellitus or secondary types of diabetes * Has a history of congestive heart failure (New York Heart Associa...
MK-1403 is being developed for the treatment of type 2 diabetes mellitus. It is an investigational small molecule that Merck & Company, Inc. is studying in adults with the condition. It has not been approved for any use and remains in clinical development.
MK-1403 is being developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker MRK. Merck is the sponsor of the clinical program evaluating the drug in type 2 diabetes mellitus.
MK-1403 is in Phase 1 clinical development. The program has completed one Phase 1 trial in participants with type 2 diabetes mellitus. MK-1403 is investigational and has not been approved by the FDA or any other regulatory authority.
MK-1403 has been studied in one Phase 1 trial, NCT07242469, titled A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006). The trial enrolled 53 participants in the United States, was randomized, double blind, and placebo controlled, and is now completed.
The Phase 1 trial of MK-1403, NCT07242469, enrolled 53 participants with type 2 diabetes mellitus. Enrollment was limited to adults 18 years and older in the United States, and healthy volunteers were not included. The study was randomized, double blind, and placebo controlled.